Main clinical features of the studies comparing DOACs with LMWH included in our meta-analysis
| . | Carney . | Leader . | Dubiski . | Lee . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Primary brain cancer . | Brain metastases . | Brain metastases . | Primary brain cancer . | Primary and brain cancer . | ||||||
| DOACs, n % . | LMWH, n % . | DOACs, n % . | LMWH, n % . | DOACs, n % . | LMWH, n % . | DOACs, n % . | LMWH, n % . | DOACs, n % . | LMWH, n % . | |
| Age, (y) | nr | nr | Nr | nr | 66 | 64 | 65 | 68 | 63 | 62 |
| Male | 50 | 66 | 48 | 50 | 66 | 51 | 43 | 38 | 56 | 54 |
| Hypertension | 75 | 23 | 71 | 39 | 49 | 28 | 36 | 38 | nr | nr |
| Chronic kidney disease | 5 | 0 | 24 | 4 | 19 | 7 | nr | nr | 19 | 8 |
| Aspirin | 20 | 9 | 52 | 5 | 5 | 4 | nr | nr | 11 | 13 |
| . | Carney . | Leader . | Dubiski . | Lee . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Primary brain cancer . | Brain metastases . | Brain metastases . | Primary brain cancer . | Primary and brain cancer . | ||||||
| DOACs, n % . | LMWH, n % . | DOACs, n % . | LMWH, n % . | DOACs, n % . | LMWH, n % . | DOACs, n % . | LMWH, n % . | DOACs, n % . | LMWH, n % . | |
| Age, (y) | nr | nr | Nr | nr | 66 | 64 | 65 | 68 | 63 | 62 |
| Male | 50 | 66 | 48 | 50 | 66 | 51 | 43 | 38 | 56 | 54 |
| Hypertension | 75 | 23 | 71 | 39 | 49 | 28 | 36 | 38 | nr | nr |
| Chronic kidney disease | 5 | 0 | 24 | 4 | 19 | 7 | nr | nr | 19 | 8 |
| Aspirin | 20 | 9 | 52 | 5 | 5 | 4 | nr | nr | 11 | 13 |
nr, not reported.